Ting-Lei Gu

Ting-Lei Gu has extensive work experience in the field of pre-clinical biology and drug discovery. Starting in 1999, they worked as a Postdoctoral Fellow at Dartmouth College and Harvard Medical School, gaining research experience. In 2004, they joined Cell Signaling Technology as a Scientist, eventually becoming a Group Leader/Principal Scientist. At Cell Signaling Technology, they led multiple projects in oncology, including antibody lead identification, target validation, and pre-clinical biomarker development. They also collaborated with academic labs for small molecule drug discovery. In 2015, Gu joined Bluefin Biomedicine, Inc. as a Principal Scientist, where they managed a group of scientists and oversaw various stages of preclinical development for therapeutic antibodies in oncology. In 2019, Gu became an Associate Director at Bluefin BioMedicine before being promoted to Director in 2020. Throughout their career, Gu has published over 20 peer-reviewed publications and demonstrated expertise in the oncology field. Prior to their research career, Gu briefly worked as an Associate at the Tuck School of Business at Dartmouth College, where they managed a group of associates and created financial projections for a manufacturing company.

Ting-Lei Gu earned a Bachelor's degree in Medicine from Shanghai Second Medical University, where they studied from 1988 to 1993. They then pursued further education at Dartmouth College, completing a PhD in Biochemistry between 1993 and 1999.